Paper Details

  1. Home
  2. Paper Details

Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.

Author: JiaTao, MaoJianping, MiaoLei, WangYing, XueLianguo, ZhuYing, ZhuYuanxin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ponatinib and dasatinib are effective treatments for central nervous system relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). Both drugs achieved a high rate of complete remission, with ponatinib showing a shorter time to remission. Ponatinib maintenance treatment may offer superior survival for patients with or without the T315I mutation. Both drugs appeared safe for clinical use.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Central nervous system leukemia (CNSL) is the most common extramedullary relapse site in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL), with a poor prognosis and high relapse rate. METHODS: We characterized the clinical data of 21 Ph-p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041591/

データ提供：米国国立医学図書館（NLM）

Treating Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparative Study

Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is a type of blood cancer that can be challenging to treat. This study investigates the efficacy and safety of two drugs, ponatinib and dasatinib, in treating Ph-positive ALL patients with central nervous system relapse. It's like comparing two different maps to find the most effective route to conquer this disease.

The results suggest that both ponatinib and dasatinib are effective in treating Ph-positive ALL, with ponatinib showing a shorter time to achieve remission. This study provides valuable insights into the treatment options for these patients, similar to discovering a hidden oasis in the desert, offering hope and relief.

New Hope for Leukemia Patients

This study provides encouraging evidence for the use of ponatinib and dasatinib in treating Ph-positive ALL. It highlights the potential of these drugs to offer a more effective and faster path to remission for patients facing this challenging disease.

Dr. Camel's Conclusion

This study provides valuable insights into the treatment landscape for Ph-positive ALL. It highlights the effectiveness of ponatinib and dasatinib, offering hope for patients battling this complex disease. This research emphasizes the ongoing quest for better treatment options and a brighter future for those affected by leukemia.

Date :
  1. Date Completed 2023-03-27
  2. Date Revised 2023-04-18
Further Info :

Pubmed ID

36959735

DOI: Digital Object Identifier

PMC10041591

Related Literature

Article Analysis
・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.